The DOI matches its Crossref record, with a small difference in title or year; 167 of the 168 references it cites were found in a registry or an index.
Management of Glomerular Proteinuria: A Commentary
Abstract
It is widely accepted that proteinuria reduction is an appropriate therapeutic goal in chronic proteinuric kidney disease. Based on large randomized controlled clinical trials (RCT), ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy have emerged as the most important antiproteinuric and renal protective interventions. However, there are numerous other interventions that have been shown to be antiproteinuric and, therefore, likely to be renoprotective. Unfortunately testing each of these antiproteinuric therapies in RCT is not feasible. The nephrologist has two choices: restrict antiproteinuric therapies to those shown to be effective in RCT or expand the use of antiproteinuric therapies to include those that, although unproven, are plausibly effective and prudent to use. The goal of this work is to provide the documentation needed for the nephrologist to choose between these strategies. This work describes 25 separate interventions that are either antiproteinuric or may block injurious mechanisms of proteinuria. Each intervention is assigned a level of recommendation (Level 1 is the highest; Level 3 is the lowest) according to the strength of the evidence supporting its antiproteinuric and renoprotective efficacy. Pathophysiologic mechanisms possibly involved are also discussed. The number of interventions at each level of recommendation are: Level 1, n = 7; Level 2, n = 9; Level 3, n = 9. Our experience indicates that we can achieve in most patients the maj…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment with oral sodium bicarbonate is an effective strategy in minimizing the risk of hyperkalemia in patients with CKD and metabolic acidosis. 82”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [82]
Citations
Cites
1 retracted
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 947
RetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Cited by
Sorted by citations
Items 201–217 of 217
Dai, Q., Zhang, P.-Q., Wang, X., Nie, L.-F., Fu, X.-J., Peng, W., Wang, Y., Li, J., Bi, Y., Mi, X., et al. (2017) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-017-2908-8
Progression of Chronic Kidney Disease and Renoprotective Therapy in Children
Wühl, E., & Schaefer, F. S. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04883-5.50051-9
Isles, C. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-03961-1.50068-4
Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis
LiYan, Y., SunJun, L., & ChenYan, L. (2012)
Floege, J., Schulze-Lohoff, E., & Weber, M. L. (2006) · Springer eBooks · doi:10.1007/3-540-26504-x_30
Prevention of the Progression of Chronic Glomerular Diseases in Children
Козыро, И. А., & Сукало, А. В. (2021) · Педиатрия. Восточная Европа · doi:10.34883/pi.2021.9.2.004
Dinesh, K., Yeun, J. Y., & Kaysen, G. A. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-685-6_20 · Cited by 1
Berden, J. H., Kuppevelt, T. H. M. S. M. V., & Rops, A. L. W. M. M. (2009) · Springer eBooks · doi:10.1007/978-3-540-29676-8_1476
Progression of Chronic Kidney Disease and Nephroprotective Therapy
Wühl, E., & Schaefer, F. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-11665-0_55
Effect of age, sex, and chronic kidney disease on urinary creatinine excretion in Japanese patients
Yasui, S., Horino, T., Mitani, K., Terada, Y., Okuhara, Y., & Hatakeyama, Y. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02569-5
Mueller, C., Neußer, T., Thate-Waschke, I.-M., Nowicki, J., Plominski, T., Griesinger, R., Kessner, S., & Martin, S. (2025) · JMIR Formative Research · doi:10.2196/60246
Gomes, V. C., Parodi, F. E., Vasan, P., Marston, W. A., Pascarella, L. E., McGinigle, K. L., Wood, J. C., Benrashid, E., & Farber, M. A. (2025) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2025.05.039
General Synthesis Method of Hantzsch dihydropyridine Using Scrap Automobile Catalyst (SAC)
Demirci, T. (2025) · Journal of the Turkish Chemical Society Section B Chemical Engineering · doi:10.58692/jotcsb.1731818
Jeon, J., & Kim, J. (2021) · Figshare · doi:10.6084/m9.figshare.14853237
Yang, F., Shi, J.-S., Gong, S.-W., Xu, X.-D., & Le, W.-B. (2022) · Figshare · doi:10.6084/m9.figshare.19092726
Jeon, J., & Kim, J. (2021) · Figshare · doi:10.6084/m9.figshare.14853234
Jeon, J., & Kim, J. (2021) · Figshare · doi:10.6084/m9.figshare.14853231
Metadata
- Authors
- Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A.
- Affiliations
- The Ohio State University Wexner Medical Center (US)
- Louis Stokes Cleveland VA Medical Center (US)
- Duke University (US)
- Alexion Pharmaceuticals (United States) (US)
- Corresponding author
- Wilmer, William A.
- Rovin, Brad H.
- Hebert, Lee A.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2003-12
- Volume
- 14
- Issue
- 12
- Pages
- 3217-3232
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2110754607
- Cited by
- 217
- References
- 168
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 3 · 2019: 8 · 2018: 3 · 2017: 4 · 2016: 7 · 2015: 8 · 2014: 6 · 2013: 19 · 2012: 14
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01dk039485-05)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01-DK55546, P01DK055546, U10 DK 48621, U01 DK 39485)
- National Center for Research Resources (M01-RR-00034, M01RR000034)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- glomerular proteinuria, proteinuria reduction, chronic kidney disease, renal protection, antiproteinuric therapy, ACE inhibitors, angiotensin receptor blockers, evidence-based recommendations, pathophysiological mechanisms
- MeSH terms
- Humans, Kidney Diseases, Kidney Glomerulus, Monitoring, Physiologic, Proteinuria, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
